Overcoming Tyrosine Kinase Inhibitor Resistance in Transformed Cell Harboring SEPT9-ABL1 Chimeric Fusion Protein

Hematological malignancies harboring various ABL1 fusions are expected to be sensitive to tyrosine kinase inhibitors (TKIs), similar to those with BCR-ABL1. However, SEPT9-ABL1 exhibits TKI resistance both in vitro and in vivo. SEPT9-ABL1 has the same ABL1 region as seen in BCR-ABL1 but no point mut...

Descripción completa

Detalles Bibliográficos
Autores principales: Kawai, Hidetsugu, Matsushita, Hiromichi, Suzuki, Rikio, Kitamura, Yuka, Ogawa, Yoshiaki, Kawada, Hiroshi, Ando, Kiyoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2019
Materias:
Original article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6611969/
https://www.ncbi.nlm.nih.gov/pubmed/31276931
http://dx.doi.org/10.1016/j.neo.2019.06.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6611969/
https://www.ncbi.nlm.nih.gov/pubmed/31276931
http://dx.doi.org/10.1016/j.neo.2019.06.001

Ejemplares similares